Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment

NCT01509911 is registered in ClinicalTrials.gov with Tiltan Pharma Ltd. as lead sponsor.

NCT NCT01509911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01509911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment
Lead sponsor
Tiltan Pharma Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2012
Completion date
January 31, 2017
Enrollment
99 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer